ID   FABPI_HUMAN             Reviewed;         132 AA.
AC   P12104; Q2NKJ1;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=Fatty acid-binding protein, intestinal;
DE   AltName: Full=Fatty acid-binding protein 2;
DE   AltName: Full=Intestinal-type fatty acid-binding protein;
DE            Short=I-FABP;
GN   Name=FABP2; Synonyms=FABPI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2824476;
RA   Sweetser D.A., Birkenmeier E.H., Klisak I.J., Zollman S.,
RA   Sparkes R.S., Mohandas T., Lusis A.J., Gordon J.I.;
RT   "The human and rodent intestinal fatty acid binding protein genes. A
RT   comparative analysis of their structure, expression, and linkage
RT   relationships.";
RL   J. Biol. Chem. 262:16060-16071(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-55.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=14563446; DOI=10.1016/S0009-9120(03)00096-1;
RA   Pelsers M.M.A.L., Namiot Z., Kisielewski W., Namiot A.,
RA   Januszkiewicz M., Hermens W.T., Glatz J.F.C.;
RT   "Intestinal-type and liver-type fatty acid-binding protein in the
RT   intestine. Tissue distribution and clinical utility.";
RL   Clin. Biochem. 36:529-535(2003).
RN   [5]
RP   INDUCTION BY EGF.
RX   PubMed=10070036;
RA   Darimont C., Gradoux N., de Pover A.;
RT   "Epidermal growth factor regulates fatty acid uptake and metabolism in
RT   Caco-2 cells.";
RL   Am. J. Physiol. 276:G606-G612(1999).
RN   [6]
RP   MUTAGENESIS OF LEU-39; GLU-64; LEU-65; VAL-67; LEU-90 AND VAL-123.
RX   PubMed=14567680; DOI=10.1021/bi0301688;
RA   Rajabzadeh M., Kao J., Frieden C.;
RT   "Consequences of single-site mutations in the intestinal fatty acid
RT   binding protein.";
RL   Biochemistry 42:12192-12199(2003).
RN   [7]
RP   STRUCTURE BY NMR.
RC   TISSUE=Intestine;
RX   PubMed=9204553; DOI=10.1023/A:1018666522787;
RA   Zhang F., Luecke C., Baier L.J., Sacchettini J.C., Hamilton J.A.;
RT   "Solution structure of human intestinal fatty acid binding protein:
RT   implications for ligand entry and exit.";
RL   J. Biomol. NMR 9:213-228(1997).
RN   [8]
RP   STRUCTURE BY NMR OF VARIANT THR-55.
RX   PubMed=12809489; DOI=10.1021/bi0273617;
RA   Zhang F., Luecke C., Baier L.J., Sacchettini J.C., Hamilton J.A.;
RT   "Solution structure of human intestinal fatty acid binding protein
RT   with a naturally-occurring single amino acid substitution (A54T) that
RT   is associated with altered lipid metabolism.";
RL   Biochemistry 42:7339-7347(2003).
RN   [9]
RP   VARIANT THR-55.
RX   PubMed=7883976; DOI=10.1172/JCI117778;
RA   Baier L.J., Sacchettini J.C., Knowler W.C., Eads J., Paolisso G.,
RA   Tataranni P.A., Mochizuki H., Bennett P.H., Bogardus C., Prochazka M.;
RT   "An amino acid substitution in the human intestinal fatty acid binding
RT   protein is associated with increased fatty acid binding, increased fat
RT   oxidation, and insulin resistance.";
RL   J. Clin. Invest. 95:1281-1287(1995).
RN   [10]
RP   VARIANT THR-55.
RX   PubMed=12899384;
RA   Kunsan X., Taisan Z., Weiping J., Duoqi S., Wei D., Jie L., Junxi L.,
RA   Rong Z.;
RT   "The association of Ala54Thr variant of intestinal fatty acid binding
RT   protein gene with general and regional adipose tissue depots.";
RL   Chin. Med. Sci. J. 14:46-51(1999).
CC   -!- FUNCTION: FABP are thought to play a role in the intracellular
CC       transport of long-chain fatty acids and their acyl-CoA esters.
CC       FABP2 is probably involved in triglyceride-rich lipoprotein
CC       synthesis. Binds saturated long-chain fatty acids with a high
CC       affinity, but binds with a lower affinity to unsaturated long-
CC       chain fatty acids. FABP2 may also help maintain energy homeostasis
CC       by functioning as a lipid sensor.
CC   -!- INTERACTION:
CC       O95994:AGR2; NbExp=6; IntAct=EBI-3905109, EBI-712648;
CC       Q9NYB0:TERF2IP; NbExp=2; IntAct=EBI-3905109, EBI-750109;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Expressed in the small intestine and at much
CC       lower levels in the large intestine. Highest expression levels in
CC       the jejunum. {ECO:0000269|PubMed:14563446}.
CC   -!- INDUCTION: By EGF. {ECO:0000269|PubMed:10070036}.
CC   -!- DOMAIN: Forms a beta-barrel structure that accommodates the
CC       hydrophobic ligand in its interior.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Fatty-acid binding
CC       protein (FABP) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18079; AAA52417.1; -; Genomic_DNA.
DR   EMBL; AC092656; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069466; AAH69466.1; -; mRNA.
DR   EMBL; BC069617; AAH69617.1; -; mRNA.
DR   EMBL; BC069625; AAH69625.1; -; mRNA.
DR   EMBL; BC069637; AAH69637.1; -; mRNA.
DR   EMBL; BC111791; AAI11792.1; -; mRNA.
DR   CCDS; CCDS3712.1; -.
DR   PIR; A29781; FZHUI.
DR   RefSeq; NP_000125.2; NM_000134.3.
DR   UniGene; Hs.282265; -.
DR   PDB; 1KZW; NMR; -; A=2-132.
DR   PDB; 1KZX; NMR; -; A=2-132.
DR   PDB; 2MJI; NMR; -; A=2-132.
DR   PDB; 2MO5; NMR; -; A=2-132.
DR   PDB; 3AKM; X-ray; 1.90 A; A/B/C/D=2-132.
DR   PDB; 3IFB; NMR; -; A=2-132.
DR   PDBsum; 1KZW; -.
DR   PDBsum; 1KZX; -.
DR   PDBsum; 2MJI; -.
DR   PDBsum; 2MO5; -.
DR   PDBsum; 3AKM; -.
DR   PDBsum; 3IFB; -.
DR   ProteinModelPortal; P12104; -.
DR   SMR; P12104; -.
DR   BioGrid; 108467; 3.
DR   IntAct; P12104; 3.
DR   STRING; 9606.ENSP00000274024; -.
DR   BindingDB; P12104; -.
DR   ChEMBL; CHEMBL4879; -.
DR   DrugBank; DB04557; Arachidonic Acid.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB08231; MYRISTIC ACID.
DR   DrugBank; DB03796; Palmitic Acid.
DR   DrugBank; DB01138; Sulfinpyrazone.
DR   SwissLipids; SLP:000001520; -.
DR   iPTMnet; P12104; -.
DR   PhosphoSitePlus; P12104; -.
DR   BioMuta; FABP2; -.
DR   DMDM; 119805; -.
DR   PaxDb; P12104; -.
DR   PeptideAtlas; P12104; -.
DR   PRIDE; P12104; -.
DR   DNASU; 2169; -.
DR   Ensembl; ENST00000274024; ENSP00000274024; ENSG00000145384.
DR   GeneID; 2169; -.
DR   KEGG; hsa:2169; -.
DR   UCSC; uc003icw.4; human.
DR   CTD; 2169; -.
DR   DisGeNET; 2169; -.
DR   GeneCards; FABP2; -.
DR   H-InvDB; HIX0004469; -.
DR   HGNC; HGNC:3556; FABP2.
DR   HPA; CAB047325; -.
DR   HPA; CAB047326; -.
DR   HPA; HPA034607; -.
DR   MIM; 134640; gene.
DR   neXtProt; NX_P12104; -.
DR   PharmGKB; PA27957; -.
DR   eggNOG; KOG4015; Eukaryota.
DR   eggNOG; ENOG4111US8; LUCA.
DR   HOGENOM; HOG000004829; -.
DR   HOVERGEN; HBG005633; -.
DR   InParanoid; P12104; -.
DR   KO; K08751; -.
DR   OrthoDB; EOG091G0QSV; -.
DR   PhylomeDB; P12104; -.
DR   TreeFam; TF316894; -.
DR   Reactome; R-HSA-163560; Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis.
DR   ChiTaRS; FABP2; human.
DR   EvolutionaryTrace; P12104; -.
DR   GeneWiki; FABP2; -.
DR   GenomeRNAi; 2169; -.
DR   PRO; PR:P12104; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000145384; -.
DR   CleanEx; HS_FABP2; -.
DR   Genevisible; P12104; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005504; F:fatty acid binding; TAS:ProtInc.
DR   GO; GO:0005215; F:transporter activity; IEA:InterPro.
DR   GO; GO:0007586; P:digestion; TAS:ProtInc.
DR   GO; GO:0019433; P:triglyceride catabolic process; TAS:Reactome.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR031272; FABP2.
DR   InterPro; IPR000463; Fatty_acid-bd.
DR   InterPro; IPR031259; ILBP.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11955; PTHR11955; 1.
DR   PANTHER; PTHR11955:SF120; PTHR11955:SF120; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PRINTS; PR00178; FATTYACIDBP.
DR   SUPFAM; SSF50814; SSF50814; 1.
DR   PROSITE; PS00214; FABP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Lipid-binding; Polymorphism; Reference proteome; Transport.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P02693}.
FT   CHAIN         2    132       Fatty acid-binding protein, intestinal.
FT                                /FTId=PRO_0000067328.
FT   BINDING      83     83       Fatty acid. {ECO:0000250}.
FT   BINDING     107    107       Fatty acid. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P02693}.
FT   VARIANT      55     55       A -> T (found in 29% of the population;
FT                                associated with increased plasma insulin
FT                                concentration, increased fat oxidation
FT                                and insulin resistance; 2-fold greater
FT                                affinity for long-chain fatty acids;
FT                                dbSNP:rs1799883).
FT                                {ECO:0000269|PubMed:12809489,
FT                                ECO:0000269|PubMed:12899384,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7883976}.
FT                                /FTId=VAR_002379.
FT   MUTAGEN      39     39       L->G: Reduced stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN      64     64       E->G: Localized reduction in stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN      65     65       L->A: Reduced stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN      65     65       L->G: Reduced stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN      67     67       V->G: Localized reduction in stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN      90     90       L->G: Reduced stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   MUTAGEN     123    123       V->G: Reduced stability.
FT                                {ECO:0000269|PubMed:14567680}.
FT   STRAND        5     14       {ECO:0000244|PDB:3AKM}.
FT   HELIX        15     22       {ECO:0000244|PDB:3AKM}.
FT   HELIX        26     32       {ECO:0000244|PDB:3AKM}.
FT   TURN         33     35       {ECO:0000244|PDB:3IFB}.
FT   STRAND       38     44       {ECO:0000244|PDB:3AKM}.
FT   STRAND       47     53       {ECO:0000244|PDB:3AKM}.
FT   STRAND       58     64       {ECO:0000244|PDB:3AKM}.
FT   STRAND       69     72       {ECO:0000244|PDB:3AKM}.
FT   STRAND       74     76       {ECO:0000244|PDB:1KZW}.
FT   STRAND       78     86       {ECO:0000244|PDB:3AKM}.
FT   STRAND       89     96       {ECO:0000244|PDB:3AKM}.
FT   TURN         97     99       {ECO:0000244|PDB:3AKM}.
FT   STRAND      102    110       {ECO:0000244|PDB:3AKM}.
FT   STRAND      113    120       {ECO:0000244|PDB:3AKM}.
FT   STRAND      123    131       {ECO:0000244|PDB:3AKM}.
SQ   SEQUENCE   132 AA;  15207 MW;  68330E3D81792CAF CRC64;
     MAFDSTWKVD RSENYDKFME KMGVNIVKRK LAAHDNLKLT ITQEGNKFTV KESSAFRNIE
     VVFELGVTFN YNLADGTELR GTWSLEGNKL IGKFKRTDNG NELNTVREII GDELVQTYVY
     EGVEAKRIFK KD
//
